New hope for Tough-to-Treat thymic cancer patients
NCT ID NCT07343453
Summary
This study is testing whether a new drug called sacituzumab tirumotecan can help control advanced thymic cancer in patients whose disease has continued to grow despite receiving at least one prior treatment. The trial will enroll 38 adults to receive the drug by IV every two weeks and will measure how many patients' tumors shrink and for how long. The main goal is to see if this treatment is effective and safe for people who have run out of standard options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC EPITHELIAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.